DWP708 for Treating Epidermal Growth Factor Receptor Inhibitor Related Skin Toxicities

Inclusion Criteria: 1. Age: older than 19 2. Eastern Cooperative Oncology Group (ECOG) performance status 0 -2 3. Patients who have Rash acneiform Gr≥2 (NCI CTCAE v5.0) 4. Patients who are currently administering EGFR TKI or EGFR mAb Exclusion Criteria: 1. Known allergies, hypersensitivity, or intolerance to study drugs, chemotherapy drugs using this clinical trial 2. Patients with a history of topical medication * Steroids within 3 days prior to baseline visit * Antihistamine, Antipruritic agents, Antibiotics agents within 1 week prior to baseline visit * Tacrolimus, Pimecrolimus within 2 weeks prior to baseline visit